Evidence map›Paper›PMID 31314075›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Adherence to Antiretroviral Therapy and Pre-exposure Prophylaxis: TARGETing the Ideal Measure.

Jose R Castillo-Mancilla

Abstract readComment
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Tenofovir alafenamide use in pregnant and lactating women living with HIV.Expert opinion on drug metabolism & toxicology · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Jose R Castillo-MancillaDivision of Infectious Diseases, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Funding

New Pharmacologic Measures of ART Adherence and Exposure: Pathway to Clinical ImplementationR01AI145453 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ANDERSON, PETER L. · 2019 to 2023
$3.7M
NIAID NIH HHS R01 AI145453
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HIV InfectionsEmtricitabineHumansPlasmaTenofovirEmtricitabineTenofoviradherenceantiretroviral therapypre-exposure prophylaxistenofovirurine

Identifiers

PMID31314075
PMCPMC7201412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.